A computational analysis to assess the ability of FDA-approved drugs to block coronavirus binding to ACE2 or transmembrane protease, serine 2 (TMPRSS2) and downstream transcriptomic profiles indicated that vitamin E, ruxolitinib and glutamine were likely to significantly attenuate infection by SARS-CoV-2 (98). The gene discussed is ACE2; the disease is infection.